Off-label use of rituximab in systemic lupus erythematosus: A systematic review

Clinical Rheumatology

Volumn 29, Issue 7, 2010, Pages 707-716

  Murray, Eleanor ^a   Perry, Martin ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

B cell depletion; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; AZATHIOPRINE; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PREDNISOLONE; RITUXIMAB; STEROID; MONOCLONAL ANTIBODY;

ABSCESS; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; B LYMPHOCYTE; BACTERIAL INFECTION; BRADYCARDIA; CANDIDIASIS; CLINICAL TRIAL; COLITIS; CONGESTIVE CARDIOMYOPATHY; CYSTITIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENTERITIS; FEBRILE NEUTROPENIA; FEVER; GRAM NEGATIVE SEPSIS; HERPES ZOSTER; HISTIOCYTOSIS; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG INFECTION; MENINGITIS; NEUTROPENIA; OFF LABEL DRUG USE; OSTEITIS; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; SEIZURE; SEPSIS; SERUM SICKNESS; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; DOWN-REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OFF-LABEL USE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77956288032     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1387-5     Document Type: Review

References (60)

1. Grammer AC, Lipsky PE (2003) B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5 (Suppl 4): S22-S27
2. Formiga F, Moga I, Pc M, Mitjavila F, Rivera A, Pujol R (1999) High disease activity at baseline does not prevent a remission in patients with systematic lupus erythematosus. Rheumatology 38:724-727
3. Danchenko N, Satia J, Satia J Athony M (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308-318
4. Kasitanon N, Magder L, Magder L, Ptri M (2006) Predictors of survival in systemic lupus erythematosus. Medicine 85(3):147-156
5. Hoyer BF, Moser K, Moser K Huser AE et al (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199:1577-1584
6. SIGN 50: A guideline developer's handbook. Annex B: Key to evidence statements and grades of recommendations. http://www.sign. ac.uk/guidelines/ fulltext/50/annexb.html
7. Clark EA, Ledbetter JA (2005) How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 64 (suppl 4): iv77-80
8. Gong Q, Ou Q, Ye, S et al (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817-826
9. Anolik JH, Campbell D, Campbell D Flgar RE, Young F, Sanz I, Rosenblatt J et al (2003) The relationship of FcgammaRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48(2):455-9
10. Barnard J, Palanichamy A, Buer JW, Anolik JH et al (2008) Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis. Poster presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, CA
11. Chan O, Madaio MP, Slomchik MJ (1999) B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol 163:3592-3596
12. Chan OTM, Hannum LG, Hannum LG Hberman AM et al (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189:1639-1648
13. Looney R, Anolik J, Anolik J Cmpbell D, Felgar R, Young F, Arend L, Sloand J, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus. A phase I/II doseescalation trial of rituximab. Arthritis Rheum 50(8):2580-2589
14. Martin F, Chan AC (2006) B cell Immunology in disease: evolving concepts from the clinic. Annual Rev Immunol 24:467-96
15. Vigna-Perez M, Hernandez-Castro B, Predes-Saharopulos O et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8(3):R83
16. Anolik JH, Barnard J, Barnard J Cppione A, Pugh-Bernard AE, Felgar RE, Looney RJ et al (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580-90
17. Anolik J, Barnard J, Barnard J, Oen T, Zheng B, Kemshetti S, Looney R, Sanz I (2007) Delayed memeory B cell recovery in peripheral blood and lymphoid tissue in systematic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56(9):3044-3056
18. Gillis J, Dall'era M, Dall'era M Goss A, Yazdany J, Davis J (2007) Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 57(3):538-542
19. Tamimoto Y, Horiuchi T, Horiuchi T, Tukamoto H et al (2008) A doseescalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology 47:821-827
20. Jonsdottir T, Gunnarsson I, Gunnarsson I, Rsselada A et al (2008) Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 67(3):330-334
21. Reynolds A, Toescu V, Ye C (2009) Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18(1):67-73
22. Edwards JC, Szczepanski L, Szczepanski L Sechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572-81
23. Bootsma H, Spronk P, Spronk P Drksen RH, et al (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595-9
24. Lu TY-T, Ng KP, Ng KP Cmbridge G, Leandro MJ, Edwards JCW, Ehrenstein M, Isenberg DA (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61(4):482-487
25. Lindholm C, Börjesson-Asp K (2008) Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. Rheumatol 35(5):826-33
26. Bombardier C, Gladman D, Gladman D Uowitz M, Caron D, Chang D, the Committee on Prognosis Studies in SLE (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-40
27. Hay E, Bacon P, Bacon P Grdon C, Isenberg D, Maddison P, Snaith M et al (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM 86:447-58
28. Karim MY, Alba P, Alba P, Cadrado M-J, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GRV (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41:876-882
29. K. Furie et al (2009) Trial design and baseline characteristics of patients in the randomised double-blind, placebo controlled phase III lupus nephritis assessment with rituximab study (LUNAR). Ann Rheum Dis 2009 (suppl 3):253.
30. LUNAR Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint. March 2009 23:13. http://www.news-medical.net/news/2009/03/11/46787. aspx. Sourced 24/05/09
31. Merrill JT, Neuwelt CM, Neuwelt CM Wllace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2008) Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phase II/III study EXPLORER. Presented at 72nd Annual Scientific Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, CA. Abstract L 12
32. Smith K, Jones R, Jones R Brns S et al (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse and retreatment. Arthritis Rheum 54(9):2970-82
33. Perry ME, Lavelle C, Lavelle C Mguire N, McKinstry Z, Paton D, Murray E, Field M (2020). Scottish use of B cell depletion therapy (rituximab) in connective tissue patients: 'real life' experience of the first 40 patients. Scottish Medical Journal (in press)
34. Weide R, Heymanns J, Heymanns J Pndorf A, Köppler H (2003) Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12:779-782
35. Tanaka Y, Yamamoto K, Yamamoto K Tkeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T (2007) A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 17:191-197
36. Albert D, Dunham J, Dunham J Kan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney R, Luning Prak E, Kimberly R, Zhang Y, Eisenberg R (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Disease 67:1724-1731
37. Sangle SR et al (2007) Rituximab in the treatment of resistant systemic lupus erythematosus: failure of therapy in rapidly progressive crescentic lupus nephritis. Arthritis Rheum 56. ACR/ARHP Abstrat 441
38. Gunnarsson I, Sundelin B, Sundelin B Jnsdottir T, Jacobson S, Henriksson E, van Vollenhoven R (2007) Histopathological and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56(4):1263-1272
39. Tokunaga M, Saito K, Saito K Kwabata D et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470-475
40. Galarza C, Valencia D, Valencia D Tbón G, Zurita L, Mantilla R, Pineda-Tamayo R, Rojas-Villarraga A, Rueda J, Anaya J (2008) Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clinic Rev Allerg Immunol 34:124-128
41. Mohd Shahrir MS, Abdul Halim AG, Abdul Halim AG Sehardy Z, Norella Kong CT (2007) Clinical experience in using CD20 monoclonal antibody in treating severe systemic lupus erythematosus. APLAR J Rheumatol 10:112-116
42. Heidel F, Lipka D, Lipka Dvn Auer C, Huber C, Scharrer I, Hess G (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97(2):228-33
43. Sfikakis PP, Boletis JN, Boletis JN Lonaki S et al (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52:501-513
44. Ceccarelli F, Perricone C, Perricone C Mssaro L et al (2009) Good safety profile of repeated b cell depletion therapy in patients with refractory systemic lupus erythematosus. Ann Rheum Dis 68 (Suppl 3):248
45. Mohrbacher A (2005) B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 7 (Suppl 3): S19-S25
46. Genentech, Inc. and Biogen Idec. http://www.news-medical.net/news/2009/ 03/11/46787.aspx
47. Li EK, am LS, Tam LS Zu TY, Li M, Kwok CL, Li TK, Leung YY, Wong KC, Szeto CC (2009) Is combination rituximab with cyclophosphamide better than rituximab alone in treatment of lupus nephritis? Rheumatology (Oxford) 48:892-8
48. Merrill J et al (2008) The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study (Abstract L15). Program and abstracts of the American College of Rheumatology 2008 Annual Scientific Meeting: San Francisco. Oct. 2008
49. Huang W, Sinha J, Sinha J Nwman J, Reddy B, Budhai L, Furie R et al (2002) The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 46:1554-62 (Pubitemid 34620202)
50. Tokunaga M, Fujii K, Fujii K Sito K et al (2005) Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 44(2):176-182
51. Gordon C et al (2009) EULAR points to consider in conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis 68:470-6
52. Strand V, Gladman D, Gladman D Ienberg D, Petri M, Smolen J, Tugwell P (2000) Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 9:322-7
53. Lavie F, Miceli-Richard C, Itah M et al (2007) Increase of B cellactivating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66(5):700-3
54. Gottenberg J, Guillevin L, Guillevin L Lmbotte O et al (2005) Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913-920
55. Boletis JN, Marinaki S, Marinaki S Salioti C, Lionaki SS, Iniotaki A, Sfikakis PP (2009) Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 24(7):2157-60
56. Catapano et al (2008) Rituximab (RTX) for refractory and relapsing SLE. American Society of Nephrology, Renal Week, 4-9 2008, SA-PO2960
57. García Hernández FJ, Ocaña Medina C, Ocaña Medina C Gnzález León R, Garrido Rasco R, Colorado Bonilla R, Castillo Palma MJ, Sánchez Román J (2007) Rituximab for treatment of patients with systemic autoimmune diseases. Med Clin (Barc) 128(12):458-62
58. Karpouzas G, Gogia M, Gogia M Mran R, Cooray D (2009) Rituximab therapy induces durable remissions in patients with refractory systemic lupus erythematosus (SLE). Ann Rheum Dis 68 (Suppl 3):248
59. Melander C et al (2009) Rituximab in severelupus nephritis: early B cell depletion affects long-term renal outcome. Clinical Journal of American Society of Nephrology 4:579-587
60. Pepper R, Griffith M, Griffith M Krwan C, Levy J, Taube D, Pusey C, Lightstone L, Cairns T (2009) Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24:3717-23